The goal of this application is to expand our interdisciplinary small animal imaging program to include complementary imaging capabilities that will increase our understanding of cancer. MR-based functional and metabolic imaging is the backbone of our current effort, which has been formalized into the Johns Hopkins pre-ICMIC. We now intend to balance that effort with a program that incorporates a strong nuclear imaging component. We intend to obtain a dedicated small animal PET device and undertake the development of a biplane x-ray/gamma scintigraphy system that will enable us to study a wider array of physiologic processes. We are also initiating a collaboration to enhance our optical imaging potential. We intend to focus on three broad areas relevant to the diagnosis and treatment of cancer: new technology development, including drug development, in-depth analysis of the tumor microenvironment, and quantification of gene expression, primarily in cells and tissues expressing the malignant phenotype. We will pursue these aims by coordinating efforts in 3 core resource facilities: (I) technology development, (II) molecular biology and (III) chemistry, all of which will support the central imaging core. A quantitative subcore will also support the imaging core. Among the 12 base grants are one center grant (the pre-ICMIC) and 3 program project grants, all of which address important questions in cancer biology and/or therapy and will be greatly enhanced by an imaging component. The combined expertise of Johns Hopkins University (JHU), the University of Virginia and the NIH will create an SAIRP with strong molecular imaging capabilities accessible to researchers in the Mid-Atlantic region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects (R24)
Project #
5R24CA092871-05
Application #
6871268
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (M1))
Program Officer
Croft, Barbara
Project Start
2001-08-27
Project End
2006-12-31
Budget Start
2005-01-12
Budget End
2005-12-31
Support Year
5
Fiscal Year
2005
Total Cost
$820,241
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Loth, Meredith K; Choi, Judy; McGlothan, Jennifer L et al. (2016) TSPO in a murine model of Sandhoff disease: presymptomatic marker of neurodegeneration and disease pathophysiology. Neurobiol Dis 85:174-186
Zhang, Yimao; Pullambhatla, Mrudula; Laterra, John et al. (2012) Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms. Mol Imaging 11:499-506
Hedvat, Michael; Emdad, Luni; Das, Swadesh K et al. (2012) Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anticancer Agents Med Chem 12:1143-55
Foss, C A; Mease, R C; Cho, S Y et al. (2012) GCPII imaging and cancer. Curr Med Chem 19:1346-59
Chen, Ying; Pullambhatla, Mrudula; Foss, Catherine A et al. (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645-53
Wilson, Brice A P; Wang, Haofan; Nacev, Benjamin A et al. (2011) High-throughput screen identifies novel inhibitors of cancer biomarker ýý-methylacyl coenzyme A racemase (AMACR/P504S). Mol Cancer Ther 10:825-38
Patil, Rajesh R; Yu, Jianhua; Banerjee, Sangeeta R et al. (2011) Probing in vivo trafficking of polymer/DNA micellar nanoparticles using SPECT/CT imaging. Mol Ther 19:1626-35
Joyal, John L; Barrett, John A; Marquis, John C et al. (2010) Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Res 70:4045-53
Banerjee, Sangeeta Ray; Pullambhatla, Mrudula; Byun, Youngjoo et al. (2010) 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 53:5333-41
Lal, Bachchu; Goodwin, C Rory; Sang, Yingying et al. (2009) EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8:1751-60

Showing the most recent 10 out of 24 publications